We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Imprimis Pharmaceuticals, Inc. (delisted) | NASDAQ:IMMY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.69 | 5.60 | 6.00 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2018
IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-35814 | 45-0567010 | ||
(State or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
12264 El Camino Real, Suite 350 | ||
San Diego, CA | 92130 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 704-4040
N/A
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.02 | Termination of a Material Definitive Agreement. |
On November 5, 2018, Imprimis Pharmaceuticals, Inc. (the “Company”) provided notice of termination to Cantor Fitzgerald & Co. (“Cantor”) of the Controlled Equity Offering SM Sales Agreement, dated November 27, 2015 (the “Sales Agreement”), by and between the Company and Cantor. The termination will become effective on November 15, 2018, following a ten-day notice period pursuant to Section 13(b) of the Sales Agreement.
The Company is terminating the Sales Agreement because it estimates that cash flow provided by operations will be sufficient to fund its operating expenses, capital expenditures and working capital requirements for at least the next twelve (12) months, and it will not need to sell its common stock through the Sales Agreement to fund its planned level of operations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMPRIMIS PHARMACEUTICALS, INC. | ||
Dated: November 6, 2018 | By: | /s/ Andrew R. Boll |
Name: | Andrew R. Boll | |
Title: | Chief Financial Officer |
1 Year Imprimis Pharmaceuticals, Inc. (delisted) Chart |
1 Month Imprimis Pharmaceuticals, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions